ReviewBiomedicines2026
Precision Diagnosis in Cutaneous Head and Neck Squamous Cell Carcinoma.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Precision oncology has been evolving rapidly, with increasing emphasis on early detection and personalized diagnostic approaches that translate into tailored treatment algorithms. The integration of molecular markers, quantitative imaging approaches and artificial intelligence (AI) in the diagnostic workflow of cutaneous squamous cell carcinoma (cSCC) has increased accuracy and has the potential to improve early detection rates in these cancers. Sun exposure is the primary etiologic factor in the development of cSCC. The primary objective of this review is to evaluate the current state and future directions of modalities and practices in diagnostic techniques for cSCC. Specifically, this review summarizes the key genetic alterations and potential molecular targets in cSCC. High-risk genetic mutations and pathways implicated in the pathogenesis of cSCC include p53, NOTCH, RAS/MAPK, cell-cycle, and adhesion pathways. This review further explores current and emerging modalities in optical imaging techniques and molecular-based diagnostic modalities in cSCC. Further, we discuss the role of radiomics and AI in the diagnostic work-up of cSCC. These techniques have the potential to enable more accurate risk models that refine conventional histopathology and guide personalized interventions. However, there are limitations to the clinical application of several of these modalities, with cost being an important driver. These challenges have been discussed in detail within this review. Nevertheless, ongoing research is focused on improving the workflow and initiating a shift in clinical practice with application of precision diagnostics as a standard of care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.